Rabbit anti-Human NLRP2 Polyclonal Antibody

Uniprot Id

Q9NX02

Target Species

Human

Target Name

NLRP2

Target Full Name

NACHT, LRR and PYD domains-containing protein 2

Target Function

Suppresses TNF- and CD40-induced NFKB1 activity at the level of the IKK complex, by inhibiting NFKBIA degradation induced by TNF. When associated with PYCARD, activates CASP1, leading to the secretion of mature proinflammatory cytokine IL1B. May be a component of the inflammasome, a protein complex which also includes PYCARD, CARD8 and CASP1 and whose function would be the activation of proinflammatory caspases.

Target Subcellular Location

Cytoplasm.

Target Protein Families

NLRP family

Target Tissue Specificity

Expressed at high levels in lung, placenta and thymus and at lower levels in ovary, intestine and brain. Highly abundant in oocytes and early embryos, however poorly expressed in somatic tissues such as brain, kidney, liver and spinal cord.

Target Synonyms

CLR19.9; FLJ20510; Leucine rich repeat and PYD containing protein 2; LRR and PYD domains-containing protein 2; NACHT; NACHT domain; NACHT leucine rich repeat and PYD containing 2; NACHT LRR and PYD domains containing protein 2; NALP2; NALP2_HUMAN; NBS1; NLR family pyrin domain containing 2; NLRP2; Nucleotide binding oligomerization domain leucine rich repeat and pyrin domain containing 2; Nucleotide-binding site protein 1; PAN1; PYPAF2; PYRIN containing APAF1 like protein2; PYRIN domain and NACHT domain-containing protein 1; PYRIN-containing APAF1-like protein 2

Target Background

This gene is a member of the nucleotide-binding and leucine-rich repeat receptor (NLR) family, and is predicted to contain an N-terminal pyrin effector domain (PYD), a centrally-located nucleotide-binding and oligomerization domain (NACHT) and C-terminal leucine-rich repeats (LRR). Members of this gene family are thought to be important regulators of immune responses. This gene product interacts with components of the IkB kinase (IKK) complex, and can regulate both caspase-1 and NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) activity. The pyrin domain is necessary and sufficient for suppression of NF-kB activity. An allelic variant (rs147585490) has been found that is incapable of blocking the transcriptional activity of NF-kB. Alternative splicing results in multiple transcript variants encoding different isoforms.